Genomics: Hepatitis C virus gets personal.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.HIV clinical trials
   Trial
2. Personalized medicine: Genetic risk prediction of drug response.Pharmacology & therapeutics · 2017
   Review
3. Search Datasets in Literature: A Case Study of GWAS.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2017
   Article
4. Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders.The international journal of neuropsychopharmacology · 2015
   Review
5. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.World journal of gastroenterology · 2013
   Article
6. Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes.World journal of gastroenterology · 2012
   Article
7. The impact of host factors on management of hepatitis C virus.Hepatitis monthly · 2012
   Article
8. Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.Journal of clinical and experimental hepatology · 2011
   Article
9. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.Journal of clinical microbiology · 2011
   Article
10. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.PloS one · 2011
    Article
11. Genome-wide association studies in pharmacogenomics.Nature reviews. Genetics · 2010
    Review

Corrections and comments

• Comment on
  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as